SciClone Pharmaceuticals (Holdings) Limited
http://www.sciclone.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SciClone Pharmaceuticals (Holdings) Limited
Deal Watch: Revance To Go Private In Crown Laboratories Buyout
Plus deals involving AstraZeneca/Conduit, Recursion/Exscientia, G1/Pharmacosmos, Sanofi/Vir, Passage Bio/GEMMA and Lupin/Evofem. Also including deals in brief.
Levicept Looks For No Pain, More Gain With Osteoarthritis Offering
The UK firm is weighing up its options for late-stage development of LEVI-04 after unveiling positive Phase II results of Phase II for the neurotrophin-3 inhibitor in moderate-to-severe osteoarthritis.
Stock Watch: Investor Reactions Diverge As J&J And Novartis Report Q2 Results
Both of the first two companies to report second-quarter financials maintained full-year sales guidance. But while Johnson & Johnson’s investors seemed cheered, Novartis’s may have been concerned about familiar issues.
Asia Deal Watch: Chugai Extends Relationship With Helsinn
Plus deals involving Kissei/JWP, Shionogi/Cilcare, Takeda/Torrent, Genome & Co./Debiopharm, Kaken/J&J, CStone/Ewopharma, MediLink/BioNTech and more.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- NovaMed Pharmaceuticals Inc.
- SciClone Pharmaceuticals Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice